Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
21 authors at 4 institutions in 5 countries.
Maurício T Tavares *Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.ORCID 0000-0002-4400-7787
Arne Krüger *Unit for Drug Discovery, Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes 1374, São Paulo, 05508-900, Brazil.ORCID 0000-0002-5531-9508
Sun L Rei YanUnit for Drug Discovery, Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes 1374, São Paulo, 05508-900, Brazil.ORCID 0000-0003-0615-4601
Karoline B WaitmanDepartment of Pharmacy, Faculty of Pharmaceutical Sciences, University of São Paulo, Av. Prof. Lineu Prestes 580, São Paulo, 05508-000, Brazil.ORCID 0000-0003-2382-534X
Vinícius M GomesGlycoProteomics Laboratory, Department of Parasitology, Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, Brazil.ORCID 0000-0001-6339-8309
Daffiny Sumam de OliveiraUnit for Drug Discovery, Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes 1374, São Paulo, 05508-900, Brazil.ORCID 0000-0003-4345-7417
Franciarli PazUnit for Drug Discovery, Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes 1374, São Paulo, 05508-900, Brazil.ORCID 0000-0001-5077-6040
Sebastian HilscherFaculty of Biosciences, Martin-Luther-University of Halle-Wittenberg, 06120, Halle/Saale, Germany.
Mike SchutkowskiFaculty of Biosciences, Martin-Luther-University of Halle-Wittenberg, 06120, Halle/Saale, Germany.ORCID 0000-0003-0919-7076
Wolfgang SipplFaculty of Biosciences, Martin-Luther-University of Halle-Wittenberg, 06120, Halle/Saale, Germany.ORCID 0000-0002-5985-9261
Claudia RuizDepartment of Molecular Medicine, The Herbert Wertheim Institute for Biomedical Innovation and Technology, Jupiter, FL, 33458, USA.
Mônica F Z J ToledoDepartment of Pharmacy, Faculty of Pharmaceutical Sciences, University of São Paulo, Av. Prof. Lineu Prestes 580, São Paulo, 05508-000, Brazil.ORCID 0000-0001-7974-4480
Neuza M A HassimottoFood Research Center-(FoRC-CEPID) and Department of Food Science and Nutrition, Faculty of Pharmaceutical Science, University of São Paulo, São Paulo, SP, Brazil.ORCID 0000-0002-5576-7693
João A Machado-NetoDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.ORCID 0000-0002-2937-8109
Antti PosoDepartment of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard-Karls-Universität, Tuebingen, Auf der Morgenstelle 8, 72076, Tübingen, Germany.ORCID 0000-0003-4196-4204
Michael D CameronDepartment of Molecular Medicine, The Herbert Wertheim Institute for Biomedical Innovation and Technology, Jupiter, FL, 33458, USA.ORCID 0000-0003-3154-4775
Thomas D BannisterDepartment of Molecular Medicine, The Herbert Wertheim Institute for Biomedical Innovation and Technology, Jupiter, FL, 33458, USA.ORCID 0000-0003-0683-8886
Giuseppe PalmisanoGlycoProteomics Laboratory, Department of Parasitology, Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, Brazil.ORCID 0000-0003-1336-6151
Carsten WrengerUnit for Drug Discovery, Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes 1374, São Paulo, 05508-900, Brazil. cwrenger@icb.usp.br.ORCID 0000-0001-5987-1749
Thales KronenbergerDepartment of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard-Karls-Universität, Tuebingen, Auf der Morgenstelle 8, 72076, Tübingen, Germany. thales.kronenberger@uni-tuebingen.de.ORCID 0000-0001-6933-7590
Roberto Parise-FilhoDepartment of Pharmacy, Faculty of Pharmaceutical Sciences, University of São Paulo, Av. Prof. Lineu Prestes 580, São Paulo, 05508-000, Brazil. roberto.parise@usp.br.ORCID 0000-0002-9311-7245
Universidade de São Paulo · BRMartin Luther University Halle-Wittenberg · DEUniversity of Eastern Finland · FIHarvard University · US
Funding
Sciex 6500+ QTrap Mass SpectrometerS10OD030332 · OD · SCRIPPS FLORIDA · PI CAMERON, MICHAEL DARIN · 2021 to 2021
$486k
NIH HHS S10 OD030332
6 · The paper itself
Abstract
We report a series of 1,3-diphenylureido hydroxamate HDAC inhibitors evaluated against sensitive and drug-resistant P. falciparum strains. Compounds 8a-d show potent antiplasmodial activity, indicating that a phenyl spacer allows improved potency relative to cinnamyl and di-hydrocinnamyl linkers. In vitro, mechanistic studies demonstrated target activity for PfHDAC1 on a recombinant level, which agreed with cell quantification of the acetylated histone levels. Compounds 6c, 7c, and 8c, identified as the most active in phenotypic assays and PfHDAC1 enzymatic inhibition. Compound 8c stands out as a remarkable inhibitor, displaying an impressive 85% inhibition of PfHDAC1, with an IC
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
1,3-Diphenylureido hydroxamate as a promising scaffold for generation of potent antimalarial histone deacetylase inhibitors. · full record | OpenQuestion